# 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

> **NCT06298916** · PHASE1,PHASE2 · RECRUITING · sponsor: **Lantheus Medical Imaging** · enrollment: 26 (estimated)

## Conditions studied

- Metastatic Sarcoma
- Esophageal Cancer
- Gastric Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Sarcoma

## Interventions

- **COMBINATION_PRODUCT:** 64Cu-LNTH-1363S

## Key facts

- **NCT ID:** NCT06298916
- **Lead sponsor:** Lantheus Medical Imaging
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2025-11
- **Final completion:** 2026-04
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06298916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06298916, "64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06298916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*